Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Summary not available.
Summary not available.
Summary not available.
Medicenna Therapeutics announced that Dr. Fahar Merchant, its President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 10:00 AM ET. The presentation will provide an overview of the company's immuno-oncology developments, including its promising MDNA11 and MDNA55 assets, focused on cancer treatment. A live webcast will be accessible here. A replay will be available post-event on Medicenna's website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced promising preclinical data for MDNA19-MDNA413, a dual-specific cytokine developed from their BiSKITs™ platform, presented at the AACR Annual Meeting. This innovative therapy selectively activates anti-cancer immune cells while inhibiting pro-tumoral macrophage polarization. Key findings highlighted a 209-fold and 90-fold enhancement in CD8/Treg and NK/Treg ratios, respectively, and effective suppression of IL-13 induced M2a macrophage polarization. Medicenna plans to advance its development and regulatory submissions for MDNA11, another promising superkine therapy.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the presentation of an abstract during the AACR Annual Meeting 2021 on April 10-15, highlighting early preclinical studies of a novel bispecific Superkine. The abstract, titled Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines, focuses on an innovative approach combining IL-2 super-agonist with IL-4/IL-13 super-antagonist. The full abstract is available on AACR's website and will be accessible on Medicenna's site post-conference.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant, CEO, will present at multiple investor conferences in March 2021. These include the H.C. Wainwright Global Life Sciences Conference, with a pre-recorded presentation available on-demand from March 9, and the Oppenheimer 31st Annual Healthcare Conference, featuring a live presentation on March 17. Additionally, Dr. Merchant will participate in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference on the same day. Details for accessing the webcasts are available on Medicenna's Investor Relations website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced that CEO Dr. Fahar Merchant will present a corporate overview at the 41st Annual Cowen Healthcare Conference on March 2, 2021, at 2:10 PM ET. Interested parties can access a live webcast here. The presentation replay will be available on Medicenna's Investor Relations page. The company focuses on immunotherapy with assets like MDNA11 and MDNA55, targeting various cancers and has obtained Fast-Track designation from the FDA.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant will present at the 10th Annual Leerink Global Healthcare Conference on February 26, 2021, at 3:00 PM ET. Investors can access a live webcast on Medicenna's Investor Relations website. Medicenna focuses on developing novel immunotherapies, including MDNA11, a long-acting IL2 Superkine, and MDNA55, which has completed a Phase 2b trial for rGBM, a deadly brain cancer. MDNA55 has received Fast-Track and Orphan Drug designation from the FDA.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) reported financial results for the quarter ended December 31, 2020, showing a net loss of $5.3 million, or $0.11 per share, compared to a loss of $2.4 million, or $0.07 per share in the same quarter of 2019. Key highlights include FDA acceptance of the hybrid trial design for MDNA55 in recurrent glioblastoma and positive feedback from the UK’s MHRA for the MDNA11 Phase 1/2 trial. The company had cash and equivalents of $33.2 million, with additional funds received post-quarter amounting to approximately $7.8 million.